ZB716, a steroidal selective estrogen receptor degrader (SERD), is orally efficacious in blocking tumor growth in mouse xenograft models

Oncotarget
Shanchun GuoGuangdi Wang

Abstract

Advances in oral SERDs development so far have been confined to nonsteroidal molecules such as those containing a cinnamic acid moiety, which are in earlystage clinical evaluation. ZB716 was previously reported as an orally bioavailable SERD structurally analogous to fulvestrant. In this study, we examined the binding details of ZB716 to the estrogen receptor alpha (ERα) by computer modeling to reveal its interactions with the ligand binding domain as a steroidal molecule. We also found that ZB716 modulates ERα-coregulator interactions in nearly identical manner to fulvestrant. The ability of ZB716 to inhibit cell growth and downregulate ER expression in endocrine resistant, ERα mutant breast cancer cells was demonstrated. Moreover, in both the MCF-7 xenograft and a patient derived xenograft model, orally administered ZB716 showed superior efficacy in blocking tumor growth when compared to fulvestrant. Importantly, such enhanced efficacy of ZB716 was shown to be attributable to its markedly higher bioavailability, as evidenced in the final plasma and tumor tissue concentrations of ZB716 in mice where drug concentrations were found significantly higher than in the fulvestrant treatment group.

References

Oct 24, 1997·Nature·A M BrzozowskiM Carlquist
Dec 20, 2002·The Oncologist·Peter F BrossRichard Pazdur
Dec 18, 2007·The Medical Letter on Drugs and Therapeutics
May 14, 2008·Proceedings of the National Academy of Sciences of the United States of America·Susie Y DaiPatrick R Griffin
Nov 21, 2009·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Feng FengJerrie Gavalchin
Mar 26, 2010·Journal of Medicinal Chemistry·Karen J KieserJohn A Katzenellenbogen
Oct 6, 2010·Chembiochem : a European Journal of Chemical Biology·Sabine MöcklinghoffLuc Brunsveld
Apr 6, 2012·ACS Medicinal Chemistry Letters·Quan JiangGuangdi Wang
Nov 5, 2013·Nature Genetics·Dan R RobinsonArul M Chinnaiyan
Nov 5, 2013·Nature Genetics·Weiyi ToySarat Chandarlapaty
Nov 26, 2013·Nature Genetics·Steffi Oesterreich, Nancy E Davidson
Jan 9, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Rinath JeselsohnVincent A Miller
May 10, 2015·Cancer Discovery
Jun 15, 2015·Breast Cancer Research and Treatment·Changde ZhangGuangdi Wang
Oct 5, 2016·Expert Opinion on Drug Metabolism & Toxicology·Stefano BoglioloBarbara Gardella

❮ Previous
Next ❯

Citations

Sep 6, 2019·Expert Opinion on Pharmacotherapy·Mohsin SolejaNisha Unni
Jun 27, 2019·Nutrients·Ryoiti Kiyama
Sep 12, 2020·ChemMedChem·Lucia Wang, Abhishek Sharma
Oct 17, 2018·Current Drug Targets·Angeles C Tecalco-CruzEduardo Cruz-Ramos
Jun 22, 2019·The Journal of Steroid Biochemistry and Molecular Biology·Diana C Márquez-GarbánRichard J Pietras
Apr 11, 2020·Anti-cancer Agents in Medicinal Chemistry·Samir H Barghout

❮ Previous
Next ❯

Methods Mentioned

BETA
xenograft
X-ray
Assay
PCR
ProteinSimple
electrophoresis

Software Mentioned

Compass
Schrodinger Suite
ProteinSimple
SA
Maestro
Glide
MMGB

Related Concepts

Related Feeds

Breast Tumorigenesis

Breast tumorigenesis involves the production or formation of tumor(s) in breast tissue. Discover the latest research on breast tumorigenesis here.